# Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

> **NCT06429787** · — · RECRUITING · sponsor: **Octapharma** · enrollment: 3574 (estimated)

## Conditions studied

- Vitamin K-Dependent Coagulation Defect
- Significant Bleeding Risk

## Interventions

- **DRUG:** Balfaxar
- **DRUG:** Kcentra

## Key facts

- **NCT ID:** NCT06429787
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-14
- **Primary completion:** 2031-12-31
- **Final completion:** 2032-06-30
- **Target enrollment:** 3574 (ESTIMATED)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06429787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06429787, "Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06429787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*